Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28005805 | 0.81 | SIGMAR1 (0.47) | SIGMAR1MC4RLMNAPOLBALDH1A1 | |
| SCHEMBL221818 | 0.79 | MC4R (0.58) | SIGMAR1MC4RLMNAPOLBMCHR1 | |
| SCHEMBL6632851 | 0.78 | POLB (0.55) | SIGMAR1LMNAPOLBALDH1A1KMT2A | |
| SCHEMBL10841960 | 0.77 | APP (0.62) | SIGMAR1MC4RLMNAPOLBMCHR1 | |
| SCHEMBL221817 | 0.77 | SIGMAR1 (0.59) | SIGMAR1MC4RLMNAPOLBMCHR1 | |
| SCHEMBL30172414 | 0.77 | MCHR1 (0.56) | SIGMAR1MC4RLMNAPOLBMCHR1 | |
| SCHEMBL930649 | 0.76 | MCHR1 (0.56) | SIGMAR1MC4RLMNAPOLBMCHR1 | |
| Hydrochloric Acid SCHEMBL10843610 | 0.76 | APP (0.61) | SIGMAR1MC4RLMNAPOLBMCHR1 | |
| SCHEMBL13698595 | 0.74 | MAPT (0.36) | POLBALDH1A1 | |
| SCHEMBL1576273 | 0.74 | SIGMAR1 (0.55) | SIGMAR1MC4RMCHR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382265-B2 | Oxazolidone compound, preparing method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361091-A1 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF | CYP3A43, CYP2C9, F2 | SIGMAR1 443/4885MC4R 407/4885LMNA 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.